Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New risk score tool aims to cut strokes in heart condition patients

NCT ID NCT03753490

Disease control Sponsor: Uppsala University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether using a personalized risk score (ABC-score) to guide treatment can lower the chance of stroke or death in people with atrial fibrillation, a common heart rhythm problem. About 3,900 participants are randomly assigned to either standard care or treatment based on their ABC-risk scores. The goal is to see if tailored recommendations for blood thinners and other therapies improve survival without major bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ABC score-guided therapy (personalized treatment recommendations based on biomarker-based risk scores)
What this could lead to
If successful, this could provide a more effective way to prevent strokes and deaths in people with atrial fibrillation by tailoring treatments to individual risk.
What could go wrong
This is a large trial but still early in testing a decision-support tool, not a drug. The approach may not significantly improve outcomes over standard care, and results may not apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 3,933 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2018

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Patients with diagnosis of atrial fibrillation, including newly diagnosed, with or without current oral anticoagulant treatment 2. Signed informed consent Exclusion criteria: 1. Contraindication for any oral anticoagulant, according to the SmPC (in Sweden FASS) 2. Indication for oral anticoagulant treatment beyond atrial fibrillation, e.g. venous thromboembolism and/or mechanical heart valve prosthesis 3. Currently on treatment with a non-vitamin K antagonist oral anticoagulant (NOAC) and not eligible for change of NOAC drug e.g. drug-drug interactions 4. Concomitant dual antiplatelet treatment 5. Acute coronary syndrome (myocardial infarction or unstable angina) within the last 30 days 6. Participation in anti-thrombotic pharmaceutical trial 7. Planned for AF ablation or AF surgery 8. Haemoglobin \<90 g/L 9. Patients who, in the opinion of the investigator, cannot or will not comply with the requirements of the protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation

Contacts and locations

Locations

  • Uppsala University Hospital

    Uppsala, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.